Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review

Pembrolizumab is widely used in first-line treatment in patients with advanced non-small-cell lung cancer (NSCLC) with high PD-L1 expression. The activity of pembrolizumab in NSCLC patients with rare molecular alterations is poorly characterised. RET gene rearrangements are identified in 1–2% of lun...

Descripción completa

Detalles Bibliográficos
Autores principales: Knetki-Wróblewska, Magdalena, Wojas-Krawczyk, Kamila, Kowalski, Dariusz M., Krzakowski, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949444/
https://www.ncbi.nlm.nih.gov/pubmed/35329956
http://dx.doi.org/10.3390/jcm11061630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949444/
https://www.ncbi.nlm.nih.gov/pubmed/35329956
http://dx.doi.org/10.3390/jcm11061630

Ejemplares similares